IAIS 2020 2nd Annual Indiana Allergy Meeting

November 7, 2020

This virtual meeting will provide learners with a range of treatments for severe atopic dermatitis, AERD, billing/coding updates and offering OIT in the medical office.

Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American College of Allergy, Asthma & Immunology (ACAAI) and the Indiana Allergy and Immunology Society. The American College of Allergy, Asthma, and Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 4.5 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity is not supported by educational grants.
 

Target Audience

Practicing allergists
Allied health professionals
 

Learning Objectives

Upon completion of this activity the participants should be able to:

  • Discuss a range of treatments available for severe atopic dermatitis and know which treatments may be best for each patient
  • Diagnose and treat AERD based on current guidelines
  • Optimise billing and coding practices, including telehealth
  • Discuss OIT options with food allergy patients

 

Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all educational planners, presenters, instructors, moderators, authors, reviewers, and other individuals in a position to control or influence the content of an activity must disclose all relevant financial relationships with any commercial interest that have occurred within the past 12 months. All identified conflicts of interest must be resolved and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure be provided to the learners prior to the start of the activity. Individuals with no relevant financial relationships must also inform the learners that no relevant financial relationships exist. Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials. Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. 

Course summary
Available credit: 
  • 4.50 AMA PRA Category 1 Credit™
  • 4.50 Attendance
Course opens: 
11/07/2020
Course expires: 
12/31/2022
Event starts: 
11/07/2020 - 8:00am CST
Event ends: 
11/07/2020 - 2:00pm CST
Rating: 
0

Justin Greiwe, MD - Speaker
Speaker/Advisory Board Member/honorarium/consulting fees: Astra Zeneca, Regeneron, Sanofi Genzyme


Tanya Laidlaw, MD – Moderator
Advisory Board Member/consulting fee: Regeneron, GlaxoSmithKline, Optinose


Andrew Blauvelt, MD – Speaker
Independent contractor/Speaker/Author/Advisory Board Member/contracted research/honorarium/consulting fees:  AbbVie

Consultant/Advisory Board Member/consulting fee/contracted research/honorarium: Pfizer
Advisory Board Member/Independent Contractor/Consultant/Author/consulting fee/honorarium/contracted research: Eli Lilly, Regeneron
Consultant/Author/Advisory Board Member/consulting fee/honorarium: Sanofi
Consultant/Author/Independent Contractor/Advisory Board Member/consulting fee, honorarium, contracted research: Leo Pharma
Consultant, Independent Contractor, Advisory Board Member/consulting fee, contracted research, honorarium: Incyte

Brian Vickery, MD – Speaker
Advisory Board Member/Clinical Investigator/Consulting fee/Contracted Research: Aimmune Therapeutics

Advisory Board Member/Consulting fee: Allergenis

The following have no relevant financial relationships to disclose:
Ann Esquivel, MD - Moderator
Kirsten Kloepfer, MD - Moderator
Christina Huddleston, MD – Speaker
Garen Wolff, MD - Speaker

Available Credit

  • 4.50 AMA PRA Category 1 Credit™
  • 4.50 Attendance
Please login or create an account to take this course.